ZA828535B - A process for preparing 3-hydroxy-ml-236b derivatives - Google Patents

A process for preparing 3-hydroxy-ml-236b derivatives

Info

Publication number
ZA828535B
ZA828535B ZA828535A ZA828535A ZA828535B ZA 828535 B ZA828535 B ZA 828535B ZA 828535 A ZA828535 A ZA 828535A ZA 828535 A ZA828535 A ZA 828535A ZA 828535 B ZA828535 B ZA 828535B
Authority
ZA
South Africa
Prior art keywords
hydroxy
derivatives
preparing
Prior art date
Application number
ZA828535A
Other languages
English (en)
Inventor
Akira Terahara
Minoru Tanaka
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of ZA828535B publication Critical patent/ZA828535B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/365—Nocardia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/872—Nocardia
ZA828535A 1981-11-20 1982-11-19 A process for preparing 3-hydroxy-ml-236b derivatives ZA828535B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56186641A JPS5889191A (ja) 1981-11-20 1981-11-20 ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法

Publications (1)

Publication Number Publication Date
ZA828535B true ZA828535B (en) 1983-10-26

Family

ID=16192138

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA828535A ZA828535B (en) 1981-11-20 1982-11-19 A process for preparing 3-hydroxy-ml-236b derivatives

Country Status (18)

Country Link
US (1) US4537859A (fr)
JP (1) JPS5889191A (fr)
KR (1) KR880002483B1 (fr)
AT (1) AT387585B (fr)
AU (1) AU551720B2 (fr)
BE (1) BE895080A (fr)
CA (1) CA1186647A (fr)
CH (1) CH651065A5 (fr)
DE (1) DE3242849A1 (fr)
DK (1) DK159328C (fr)
ES (1) ES517542A0 (fr)
FI (1) FI70925C (fr)
FR (1) FR2516935A1 (fr)
GB (1) GB2111052B (fr)
IT (1) IT1191235B (fr)
NL (1) NL194373C (fr)
SE (1) SE453996B (fr)
ZA (1) ZA828535B (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE69602T1 (de) * 1985-09-13 1991-12-15 Sankyo Co Hydroxy-ml-236b-derivate, deren herstellung und anwendung.
USRE36481E (en) * 1986-06-23 2000-01-04 Merck & Co., Inc. HMG-CoA reductase inhibitors
US4940727A (en) * 1986-06-23 1990-07-10 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US5116870A (en) * 1986-06-23 1992-05-26 Merck & Co., Inc. HMG-CoA reductase inhibitors
US4833258A (en) * 1987-02-17 1989-05-23 Merck & Co., Inc. Intermediates useful in the preparation of HMG-COA reductase inhibitors
EP0306263B1 (fr) * 1987-09-02 1992-03-18 Merck & Co. Inc. Inhibiteurs d'HMG-COA réductase
US4997848A (en) 1987-10-27 1991-03-05 Sankyo Company, Limited Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition
US4997755A (en) * 1988-04-15 1991-03-05 Merck & Co., Inc. HMG-CoA reductase inhibitors produced by Nocardia sp. (MA 6455)
EP0337548A3 (fr) * 1988-04-15 1991-08-14 Merck & Co. Inc. Inhibiteurs d'HMG-COA-réductase, produits par nocardia SP. (MA6455)(ATCC 53695)
US4963538A (en) * 1988-06-29 1990-10-16 Merck & Co., Inc. 5-oxygenated HMG-CoA reductase inhibitors
US4937259A (en) * 1989-06-09 1990-06-26 Merck & Co., Inc. Antihypercholesterolemic compounds
US5001241A (en) * 1989-06-09 1991-03-19 Merck & Co., Inc. 3-KETO HMG-CoA reductase inhibitors
US5041562A (en) * 1989-06-09 1991-08-20 Merck & Co., Inc. 3-keto HMG-CoA reductase inhibitors
US5010105A (en) * 1989-06-09 1991-04-23 Merck & Co., Inc. Antihypercholesterolemic compounds
US4970231A (en) * 1989-06-09 1990-11-13 Merck & Co., Inc. 4-substituted HMG-CoA reductase inhibitors
US4997849A (en) * 1989-06-23 1991-03-05 Merck & Co., Inc. Microbial transformation of simvastatin
US4965200A (en) * 1989-06-23 1990-10-23 Merck & Co., Inc. Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs
US5112857A (en) * 1990-09-04 1992-05-12 Merck & Co., Inc. Hmg-coa reductase inhibitor metabolites
NZ250609A (en) * 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
US6043064A (en) * 1993-10-22 2000-03-28 Bristol-Myers Squibb Company Enzymatic hydroxylation process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof
US5942423A (en) 1995-06-07 1999-08-24 Massachusetts Institute Of Technology Conversion of compactin to pravastatin by actinomadura
SI9800144A (sl) * 1998-05-21 1999-12-31 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Nov biotehnološki postopek pridobivanja 3-hidroksi-ML-236B derivatov poznanih kot M-4 in M-4'
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
US6946270B1 (en) * 1999-01-20 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Process for producing HMG-CoA reductase inhibitors
HUP0105145A3 (en) * 1999-01-29 2006-02-28 Kyowa Hakko Kogyo Kk Process for producing hmg-coa reductase inhibitor
US6682913B1 (en) 1999-02-03 2004-01-27 Institute For Drug Research Ltd. Microbial process for preparing pravastatin
HUP9902352A1 (hu) * 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására
IL155194A0 (en) * 2000-10-05 2003-11-23 Biogal Pharmaceutical Co Ltd Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
JP3236282B1 (ja) * 2000-10-16 2001-12-10 三共株式会社 プラバスタチンを精製する方法
JP2003093045A (ja) * 2001-09-26 2003-04-02 Godo Shusei Co Ltd 有用変換微生物
AU2003226051A1 (en) * 2002-04-16 2003-11-03 Banyu Pharmaceutical Co., Ltd. Solid forms of salts with tyrosine kinase activity
US20040198800A1 (en) * 2002-12-19 2004-10-07 Geoffrey Allan Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
MXPA05005813A (es) 2002-12-20 2005-12-12 Pfizer Prod Inc Formas de dosificacion que comprenden un inhibidor de la cetp y un inhibidor de la hmg-coa reductasa.
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
KR100470078B1 (ko) * 2003-06-12 2005-02-04 씨제이 주식회사 컴팩틴을 프라바스타틴으로 전환할 수 있는 스트렙토마이세스 종(Ｓｔｒｅｐｔｏｍｙｃｅｓ ｓｐ.)ＣＪＰＶ 975652 및 그를 이용한 프라바스타틴의 제조방법
CA2535359A1 (fr) 2003-08-21 2005-03-03 Merck Frosst Canada Ltd. Inhibiteurs de cathepsine et de cysteine protease
US20050101927A1 (en) * 2003-09-11 2005-05-12 Kimberly-Clark Worldwide, Inc. Absorbent products comprising a moisturizing and lubricating composition
BRPI0416639A (pt) 2003-11-19 2007-01-16 Metabasis Therapeutics Inc tiromiméticos contendo fósforo
TWI252253B (en) * 2004-01-09 2006-04-01 Chinese Petroleum Corp A novel Pseudonocardia sp RMRC PAH4 and a process for bioconverting compactin into pravastatin using the same
US20110217412A1 (en) * 2004-07-30 2011-09-08 Jinis Biopharmaceuticals Co. Cholesterol lowering supplement and low cholesterol egg produced by using the same
KR100637762B1 (ko) * 2004-07-30 2006-10-23 주식회사 지니스 저콜레스테롤 란을 생산하기 위한 가금류용 사료첨가제 및 이를 이용한 저콜레스테롤 란의 생산방법
TWI307360B (en) 2004-12-03 2009-03-11 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Process for constructing strain having compactin hydroxylation ability
NZ555316A (en) 2004-12-09 2009-08-28 Merck & Co Inc Estrogen receptor modulators
DK1855674T3 (da) 2005-03-02 2014-10-20 Merck Sharp & Dohme Sammensætning til hæmning af cathepsin k
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
MX2008013427A (es) 2006-04-19 2008-11-04 Novartis Ag Compuestos de benzoxazole y benzotiazole sustituidos-6-0 y metodos para inhibir la señalizacion csf-1r.
WO2008039327A2 (fr) 2006-09-22 2008-04-03 Merck & Co., Inc. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
WO2008084261A1 (fr) 2007-01-10 2008-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Indazoles à substitution amide utilisés comme inhibiteurs de la poly(adp-ribose)polymérase (parp)
BRPI0808523A2 (pt) 2007-03-01 2014-08-19 Novartis Vaccines & Diagnostic Inibidores de pim cinase e métodos de seu uso
CA2685967A1 (fr) 2007-05-21 2008-11-21 Novartis Ag Inhibiteurs de cfs-1r, compositions et methodes d'utilisation connexes
EP2170076B1 (fr) 2007-06-27 2016-05-18 Merck Sharp & Dohme Corp. Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase
PT2222636E (pt) 2007-12-21 2013-07-16 Ligand Pharm Inc Moduladores seletivos de recetores de andrógeno (sarms) e suas utilizações
JP5616328B2 (ja) * 2008-04-25 2014-10-29 株式会社アモーレパシフィックＡｍｏｒｅｐａｃｉｆｉｃ Ｃｏｒｐｏｒａｔｉｏｎ 生体内変換システムを利用したオルソ−ジヒドロキシイソフラボンの製造方法
WO2010093601A1 (fr) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Nouveaux thyromimetiques contenant de l'acide sulfonique et methodes d'utilisation associees
WO2010114780A1 (fr) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité akt
NZ599343A (en) 2009-10-14 2014-05-30 Merck Sharp & Dohme Substituted piperidines that increase p53 activity and the uses thereof
WO2011163330A1 (fr) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
RU2624045C2 (ru) 2010-08-17 2017-06-30 Сирна Терапьютикс,Инк ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
EP2608669B1 (fr) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
WO2012030685A2 (fr) 2010-09-01 2012-03-08 Schering Corporation Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
WO2012036997A1 (fr) 2010-09-16 2012-03-22 Schering Corporation Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
WO2012058210A1 (fr) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA)
EP2654748B1 (fr) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
WO2012112363A1 (fr) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Inhibiteurs de cystéine protéases, les cathepsines
US20140045832A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Insulin-Like Growth Factor-1 Receptor Inhibitors
WO2013063214A1 (fr) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
EP3358013B1 (fr) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
PT2925888T (pt) 2012-11-28 2017-12-13 Merck Sharp & Dohme Composições e métodos para tratamento do cancro
CA2895504A1 (fr) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Imidazopyridines substituees en tant qu'inhibiteurs de hdm2
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP3055314B1 (fr) 2013-10-08 2018-09-12 Merck Sharp & Dohme Corp. Inhibiteurs de cysteine protease de type cathepsine
WO2015051479A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Inhibiteurs de cystéine-protéases de type cathepsines
EP3613418A1 (fr) 2014-01-17 2020-02-26 Ligand Pharmaceuticals, Inc. Procédés et compositions de modulation des niveaux d'hormones
WO2015120580A1 (fr) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Inhibiteurs de protéases à cystéine de type cathépsines
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3833667B1 (fr) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
WO2020033282A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
KR20220123229A (ko) 2019-12-17 2022-09-06 머크 샤프 앤드 돔 엘엘씨 Prmt5 억제제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3392171A (en) * 1964-03-20 1968-07-09 Upjohn Co 4-morpholino-4'-hydroxy bicyclohexyls
US3281330A (en) * 1964-03-20 1966-10-25 Upjohn Co Microbiological process for the oxygenation of cycloalkanes
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b

Also Published As

Publication number Publication date
AU551720B2 (en) 1986-05-08
ES8402350A1 (es) 1984-01-16
CH651065A5 (de) 1985-08-30
KR840002451A (ko) 1984-07-02
FI823978A0 (fi) 1982-11-19
CA1186647A (fr) 1985-05-07
JPS5889191A (ja) 1983-05-27
IT8268359A0 (it) 1982-11-22
KR880002483B1 (ko) 1988-11-19
ES517542A0 (es) 1984-01-16
DK516182A (da) 1983-05-21
DE3242849C2 (fr) 1989-01-05
DE3242849A1 (de) 1983-06-01
FI70925B (fi) 1986-07-18
IT1191235B (it) 1988-02-24
JPH0371116B2 (fr) 1991-11-12
DK159328B (da) 1990-10-01
NL194373B (nl) 2001-10-01
FI70925C (fi) 1986-10-27
US4537859A (en) 1985-08-27
AT387585B (de) 1989-02-10
SE8206580D0 (sv) 1982-11-18
SE8206580L (sv) 1983-05-21
ATA425182A (de) 1988-07-15
NL8204505A (nl) 1983-06-16
NL194373C (nl) 2002-02-04
FR2516935B1 (fr) 1985-02-08
FR2516935A1 (fr) 1983-05-27
FI823978L (fi) 1983-05-21
DK159328C (da) 1991-02-25
BE895080A (fr) 1983-03-16
AU9061082A (en) 1983-05-26
GB2111052A (en) 1983-06-29
SE453996B (sv) 1988-03-21
GB2111052B (en) 1985-05-09

Similar Documents

Publication Publication Date Title
ZA828535B (en) A process for preparing 3-hydroxy-ml-236b derivatives
GB2101866B (en) A process for preparing cheese-base
PT74504A (en) Process for preparing imidazodiazepines
GB2110688B (en) A process for preparing 3-alkoxymethylcephalosporin derivatives
GB2108959B (en) A process for producing a 3-chloro-5-trifluoromethylpyridine derivative
HU185109B (en) Process for preparing imidazo-quinazoline derivatives
DE3272283D1 (en) A process for preparing chromans
PT74387B (en) Process for preparing a pyrrolidine derivative
DE3268413D1 (en) Process for preparing chlorotrifluoromethylbenzene
DE3261535D1 (en) Process for preparing aryldiazosulphonates
PT75680A (en) Process for preparing 5-phenyl-2s-pentanol
GB2108491B (en) Process for preparing 3-exo-methylenecepham derivatives
DE3261580D1 (en) Process for preparing 4-haloazetidin-2-ones
EG15730A (en) Process for preparing a arasin
PT75274A (en) Process for preparing a new vincamin derivative
DE3273038D1 (en) A method for preparing 1-aryl-3-arylamino-2-pyrazolin-5-ones
GB2108492B (en) Process for preparing oxazolineazetidinone derivatives
DE3262826D1 (en) Process for preparing m-alkylhydroxybenzene
DE3267381D1 (en) Process for preparing beta-chloroalanine
GB2112777B (en) Process for preparing mononitrochlorobenzene
GB2108110B (en) Process for preparing 2-oxycephalosporin derivatives
EG16841A (en) A process for preparing 2-dioxacycloalkylthiop derivatives
DE3260363D1 (en) Process for preparing 3-alkylaminophenols
DE3263884D1 (en) Process for preparing alpha-omega-bis-flurosulfato-perfluoroalkanes
PL239428A1 (en) Process for preparing pyrbuterol